Retatrutide
Triple-agonist targeting GLP-1, GIP, and glucagon receptors for powerful metabolic effects
Clinical Research Score: 4/5 — Backed by Phase 2 NEJM trials showing dramatic weight loss; still investigational and awaiting later-stage approval.
Categories: Weight Loss / Metabolic
What is Retatrutide?
Retatrutide may be the most powerful weight loss compound ever studied. Phase 2 trials showed up to 24% body weight reduction at 48 weeks — numbers that surpass every other medication and peptide in head-to-head comparison. It achieves this by attacking metabolism from three directions at once.
People report profound appetite suppression — even more dramatic than tirzepatide. Fat loss is rapid and sustained. Metabolic markers improve across the board. Energy levels remain stable despite significant calorie reduction. Liver fat decreases substantially, which is important for metabolic health beyond just weight.
What makes retatrutide unique is the glucagon receptor activation — the third pathway. While GLP-1 and GIP reduce appetite and improve insulin function, glucagon activation increases energy expenditure (your body burns more calories at rest) and promotes fat burning in the liver. It's attacking the problem from both sides: eating less AND burning more. For those seeking maximum weight loss and metabolic transformation, retatrutide represents the current frontier.
How Retatrutide works
Retatrutide simultaneously activates three receptors: GLP-1R (suppressing appetite and improving insulin secretion), GIPR (enhancing insulin sensitivity and potentially preserving lean mass), and GCGR — the glucagon receptor — which increases energy expenditure, promotes the liver to burn stored fat, and enhances thermogenesis. This triple mechanism provides both reduced intake (eating less) and increased expenditure (burning more), creating a larger energy deficit than any single or dual-agonist approach.
Scientific overview
Retatrutide (LY3437943) is a novel triple hormone receptor agonist developed by Eli Lilly that simultaneously activates GLP-1, GIP, and glucagon receptors. This triple mechanism provides synergistic metabolic benefits — GLP-1 and GIP receptor activation suppresses appetite and improves insulin sensitivity, while glucagon receptor agonism increases energy expenditure and promotes hepatic fat oxidation. Phase 2 trials demonstrated up to 24% body weight loss at 48 weeks.
Dosing
- Starting dose: 0.5 mg per week
- Common dosage range: 0.5-12 mg per week (titrated)
- Administration: Subcutaneous
- Half-life: ~6 days
- Frequency: Once weekly